Peripheral T-Cell Lymphomas PTCL-Pipeline Review, H1 2016

Peripheral T-Cell Lymphomas PTCL-Pipeline Review, H1 2016

  • Products Id :- GMDHC7729IDB
  • |
  • Pages: 226
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary


Global Markets Direct's, 'Peripheral T-Cell Lymphomas (PTCL)-Pipeline Review, H1 2016', provides an overview of the Peripheral T-Cell Lymphomas (PTCL) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peripheral T-Cell Lymphomas (PTCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Peripheral T-Cell Lymphomas (PTCL)

The report reviews pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Peripheral T-Cell Lymphomas (PTCL) therapeutics and enlists all their major and minor projects

The report assesses Peripheral T-Cell Lymphomas (PTCL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL)

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Peripheral T-Cell Lymphomas (PTCL)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Peripheral T-Cell Lymphomas (PTCL) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Peripheral T-Cell Lymphomas (PTCL) Overview 9

Therapeutics Development 10

Pipeline Products for Peripheral T-Cell Lymphomas (PTCL)-Overview 10

Peripheral T-Cell Lymphomas (PTCL)-Therapeutics under Development by Companies 11

Peripheral T-Cell Lymphomas (PTCL)-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Peripheral T-Cell Lymphomas (PTCL)-Products under Development by Companies 16

Peripheral T-Cell Lymphomas (PTCL)-Companies Involved in Therapeutics Development 18

AB Science SA 18

Affimed Therapeutics AG 19

Bayer AG 20

Celgene Corporation 21

CerRx, Inc. 22

Chipscreen Biosciences Ltd 23

Eisai Co., Ltd. 24

Incyte Corporation 25

Johnson & Johnson 26

Karyopharm Therapeutics, Inc. 27

Mundipharma International Ltd 28

Ono Pharmaceutical Co., Ltd. 29

Onxeo SA 30

Pfizer Inc. 31

Rhizen Pharmaceuticals S.A. 32

Seattle Genetics, Inc. 33

Solasia Pharma K.K. 34

Spectrum Pharmaceuticals, Inc. 35

TG Therapeutics, Inc. 36

Peripheral T-Cell Lymphomas (PTCL)-Therapeutics Assessment 37

Assessment by Monotherapy Products 37

Assessment by Target 38

Assessment by Mechanism of Action 41

Assessment by Route of Administration 43

Assessment by Molecule Type 45

Drug Profiles 47

AFM-13-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

belinostat-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

brentuximab vedotin-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

copanlisib hydrochloride-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

CS-055-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

darinaparsin-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

denileukin diftitox-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

fenretinide-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

forodesine hydrochloride-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

lenalidomide-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

masitinib-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

mitoxantrone hydrochloride-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

nivolumab-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

NL-101-Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

pralatrexate-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

romidepsin-Drug Profile 99

Product Description 99

Mechanism of Action 99

R&D Progress 99

RP-6530-Drug Profile 102

Product Description 102

Mechanism of Action 102

R&D Progress 102

ruxolitinib phosphate-Drug Profile 103

Product Description 103

Mechanism of Action 103

R&D Progress 103

selinexor-Drug Profile 108

Product Description 108

Mechanism of Action 108

R&D Progress 108

SH-7129-Drug Profile 114

Product Description 114

Mechanism of Action 114

R&D Progress 114

temsirolimus-Drug Profile 116

Product Description 116

Mechanism of Action 116

R&D Progress 116

TGR-1202-Drug Profile 118

Product Description 118

Mechanism of Action 118

R&D Progress 118

tipifarnib-Drug Profile 121

Product Description 121

Mechanism of Action 121

R&D Progress 121

Peripheral T-Cell Lymphomas (PTCL)-Recent Pipeline Updates 124

Peripheral T-Cell Lymphomas (PTCL)-Dormant Projects 213

Peripheral T-Cell Lymphomas (PTCL)-Discontinued Products 214

Peripheral T-Cell Lymphomas (PTCL)-Product Development Milestones 215

Featured News & Press Releases 215

Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan 215

Dec 07, 2015: Seattle Genetics Highlights ADCETRIS Data Presentations in Frontline Non-Hodgkin Lymphoma at ASH 2015 215

Dec 06, 2015: Spectrum Pharmaceuticals and Onxeo Announce Complete Response in 67% of Patients with Peripheral T-Cell Lymphoma in Combination of Belinostat and Standard CHOP 217

Nov 09, 2015: Onxeo Reports Initial Results of Phase 1 Trial Evaluating Belinostat in Combination with CHOP in Peripheral T-cell Lymphoma 218

Sep 30, 2015: Kura Oncology Initiates Phase 2 Study of Tipifarnib in Peripheral T-cell Lymphoma 220

Jun 23, 2015: Beleodaq (belinostat) pivotal BELIEF study results published in the Journal of Clinical Oncology 220

May 27, 2015: AB Science: Phase 2 with masitinib in peripheral T-cell lymphoma accelerated into phase 3 221

Jan 09, 2015: Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China 223

Dec 09, 2014: Combination of ISTODAX (romidepsin) and Standard CHOP Demonstrates a Complete Response in 51% of Patients with Peripheral T-Cell Lymphoma 223

Dec 05, 2014: Spectrum Pharmaceuticals Highlights Abstracts on Beleodaq (belinostat) at the 56th Annual Meeting of the ASH in San Francisco 224

Appendix 225

Methodology 225

Coverage 225

Secondary Research 225

Primary Research 225

Expert Panel Validation 225

Contact Us 225

Disclaimer 226

List of Figures

Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H1 2016 10

Number of Products under Development by Companies, H1 2016 11

Comparative Analysis by Clinical Stage Development, H1 2016 14

Comparative Analysis by Early Stage Products, H1 2016 15

Assessment by Monotherapy Products, H1 2016 37

Number of Products by Top 10 Targets, H1 2016 38

Number of Products by Stage and Top 10 Targets, H1 2016 38

Number of Products by Top 10 Mechanism of Actions, H1 2016 41

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 41

Number of Products by Routes of Administration, H1 2016 43

Number of Products by Stage and Routes of Administration, H1 2016 43

Number of Products by Molecule Types, H1 2016 45

Number of Products by Stage and Molecule Types, H1 2016 45

List of Tables

Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H1 2016 10

Number of Products under Development by Companies, H1 2016 12

Comparative Analysis by Late Stage Development, H1 2016 13

Comparative Analysis by Clinical Stage Development, H1 2016 14

Comparative Analysis by Early Stage Development, H1 2016 15

Products under Development by Companies, H1 2016 16

Products under Development by Companies, H1 2016 (Contd..1) 17

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by AB Science SA, H1 2016 18

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Affimed Therapeutics AG, H1 2016 19

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Bayer AG, H1 2016 20

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Celgene Corporation, H1 2016 21

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by CerRx, Inc., H1 2016 22

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Chipscreen Biosciences Ltd, H1 2016 23

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Eisai Co., Ltd., H1 2016 24

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Incyte Corporation, H1 2016 25

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Johnson & Johnson, H1 2016 26

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Karyopharm Therapeutics, Inc., H1 2016 27

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Mundipharma International Ltd, H1 2016 28

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 29

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Onxeo SA, H1 2016 30

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Pfizer Inc., H1 2016 31

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Rhizen Pharmaceuticals S.A., H1 2016 32

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Seattle Genetics, Inc., H1 2016 33

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Solasia Pharma K.K., H1 2016 34

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 35

Peripheral T-Cell Lymphomas (PTCL)-Pipeline by TG Therapeutics, Inc., H1 2016 36

Assessment by Monotherapy Products, H1 2016 37

Number of Products by Stage and Target, H1 2016 39

Number of Products by Stage and Mechanism of Action, H1 2016 42

Number of Products by Stage and Route of Administration, H1 2016 44

Number of Products by Stage and Molecule Type, H1 2016 46

Peripheral T-Cell Lymphomas (PTCL) Therapeutics-Recent Pipeline Updates, H1 2016 124

Peripheral T-Cell Lymphomas (PTCL)-Dormant Projects, H1 2016 213

Peripheral T-Cell Lymphomas (PTCL)-Discontinued Products, H1 2016 214

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

AB Science SA Affimed Therapeutics AG Bayer AG Celgene Corporation CerRx, Inc. Chipscreen Biosciences Ltd Eisai Co., Ltd. Incyte Corporation Johnson & Johnson Karyopharm Therapeutics, Inc. Mundipharma International Ltd Ono Pharmaceutical Co., Ltd. Onxeo SA Pfizer Inc. Rhizen Pharmaceuticals S.A. Seattle Genetics, Inc. Solasia Pharma K.K. Spectrum Pharmaceuticals, Inc. TG Therapeutics, Inc.

Peripheral T-Cell Lymphomas (PTCL) Therapeutic Products under Development, Key Players in Peripheral T-Cell Lymphomas (PTCL) Therapeutics, Peripheral T-Cell Lymphomas (PTCL) Pipeline Overview, Peripheral T-Cell Lymphomas (PTCL) Pipeline, Peripheral T-Cell Lymphomas (PTCL) Pipeline Assessment

select a license
Single User License
USD 2000 INR 143800
Site License
USD 4000 INR 287600
Corporate User License
USD 6000 INR 431400



I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]